{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:02:44Z","timestamp":1793646164089,"version":"4.5.1"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen\u2019s ability to induce dystrophin expression and examined its safety in DMD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this open\u2010label, multicenter, parallel\u2010group, phase 1\/2, exploratory study, 16 ambulant and nonambulant males aged 5\u201312\u00a0years with DMD received viltolarsen 40 or 80\u00a0mg\/kg\/week via intravenous infusion for 24\u00a0weeks. Primary endpoints were dystrophin expression and exon 53 skipping levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In western blot analysis, mean changes in dystrophin expression (% normal) from baseline to Weeks 12 and 24 were\u00a0\u2212\u00a01.21 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.5136) and 1.46 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.1636), respectively, in the 40\u00a0mg\/kg group, and 0.76 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.2367) and 4.81 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0536), respectively, in the 80\u00a0mg\/kg group. The increase in mean dystrophin level at Weeks 12 and 24 was significant in the 80\u00a0mg\/kg group (2.78%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0364). Patients receiving 80\u00a0mg\/kg showed a higher mean exon 53 skipping level (42.4%) than those receiving 40\u00a0mg\/kg (21.8%). All adverse events were judged to be mild or moderate in intensity and none led to study discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Treatment with viltolarsen 40 or 80\u00a0mg\/kg elicited an increasing trend in dystrophin expression and exon 53 skipping levels, and was safe and well tolerated. The decline in motor function appeared less marked in patients with higher dystrophin levels; this may warrant further investigation. This study supports the potential clinical benefit of viltolarsen.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acn3.51235","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:48:01Z","timestamp":1607370481000},"page":"2393-2408","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-1417","authenticated-orcid":false,"given":"Hirofumi","family":"Komaki","sequence":"first","affiliation":[{"name":"Translational Medical Center National Center of Neurology and Psychiatry Kodaira Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hyogo College of Medicine Nishinomiya Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Neurology National Hospital Organization Osaka Toneyama Medical Center Toyonaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Ozasa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Kumamoto University Hospital Kumamoto Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Funato","sequence":"additional","affiliation":[{"name":"Department of Pediatrics National Hospital Organization Nagara Medical Center Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Child Neurology National Center of Neurology and Psychiatry National Center Hospital Kodaira Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation National Center of Neurology and Psychiatry National Center Hospital Kodaira Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation National Center of Neurology and Psychiatry National Center Hospital Kodaira Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Egawa","sequence":"additional","affiliation":[{"name":"Global Clinical Development Department Nippon Shinyaku Co., Ltd. Kyoto Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Toramoto","sequence":"additional","affiliation":[{"name":"Global Clinical Development Department Nippon Shinyaku Co., Ltd. Kyoto Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Tajima","sequence":"additional","affiliation":[{"name":"Global Clinical Development Department Nippon Shinyaku Co., Ltd. Kyoto Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Takeda","sequence":"additional","affiliation":[{"name":"National Center of Neurology and Psychiatry Kodaira Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1113\/EP085308"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90504-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-02-0112"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140048"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/965631"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.03.008"},{"key":"e_1_2_8_10_1","unstructured":"Japanese Society of Neurology Japanese Society of Child Neurology National Center of Neurology and Psychiatry Nankodo:Clinical care and treatment guideline for Duchenne Muscular Dystrophy 2014. Available athttps:\/\/www.neurology\u2010jp.org\/guidelinem\/dmd.html."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25083"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0682"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2017.57"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713"},{"key":"e_1_2_8_16_1","first-page":"1","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy [published online ahead of print, 2020 Mar 5]","volume":"00","author":"Frank DE","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2012.01250.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_2_8_20_1","unstructured":"EXONDYS 51TM.Highlights of prescribing information revised September2016. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/206488lbl.pdf."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805263182104"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306350"},{"issue":"01","key":"e_1_2_8_23_1","first-page":"S1","article-title":"Very low residual dystrophin levels mitigate dystrophinopathy towards Becker muscular dystrophy","volume":"50","author":"Feraudy Y","year":"2019","journal-title":"Neuropediatrics"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23561"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195850"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-140002"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0408-z"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.51235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.51235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T13:06:38Z","timestamp":1693832798000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.51235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/acn3.51235"],"URL":"https:\/\/doi.org\/10.1002\/acn3.51235","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2020-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}